Ditto Bio blog · Mar 2026
First company blog post on MoleculeMapper and how Ditto maps parasite proteins to human targets to improve autoimmune target selection.
Evolutionary therapies for autoimmune disease
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Ditto Biosciences (Ditto Bio) is a 2025 San Francisco biotech backed by Y Combinator that uses AI plus parasite biology to discover and engineer autoimmune therapeutics.
Primary product
MoleculeMapper, an AI platform for mapping parasite proteins to human targets and surfacing autoimmune drug candidates
Founded
2025
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
AI-enabled drug discovery for autoimmune therapeutics
Business model
AI-enabled drug discovery platform
Open Positions
17 jobs at Ditto Biosciences
Vice President of Marketing
On-siteMarketingRemote (Atlanta, Austin, San Francisco, Seattle)Today
On-site